Epizyme Inc. [NASDAQ: EPZM] closed the trading session at $5.73 on 09/17/21. The day’s price range saw the stock hit a low of $5.28, while the highest price level was $5.75. The company report on September 14, 2021 that Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress.
Two Poster Presentations for Tazemetostat, a Methyltransferase Inhibitor, in Metastatic Castration-Resistant Prostate Cancer and in Combinations in Patients with Solid Tumors.
Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, announced that clinical data will be presented at the upcoming 2021 European Society of Medical Oncology (ESMO) Virtual Congress, taking place on September 16-21, 2021.
The stocks have a year to date performance of -47.24 percent and weekly performance of 5.33 percent. The stock has been moved at -36.19 percent over the last six months. The stock has performed 12.35 percent around the most recent 30 days and changed -33.29 percent over the most recent 3-months.
If compared to the average trading volume of 1.15M shares, EPZM reached to a volume of 2419310 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Epizyme Inc. [EPZM]:
SVB Leerink have made an estimate for Epizyme Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 07, 2021. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on April 23, 2021, representing the official price target for Epizyme Inc. stock. Previously, the target price had yet another raise to $13, while Credit Suisse analysts kept a Outperform rating on EPZM stock.
The Average True Range (ATR) for Epizyme Inc. is set at 0.26, with the Price to Sales ratio for EPZM stock in the period of the last 12 months amounting to 16.97. The Price to Book ratio for the last quarter was 18.48, with the Price to Cash per share for the same quarter was set at 2.53.
EPZM stock trade performance evaluation
Epizyme Inc. [EPZM] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.33. With this latest performance, EPZM shares gained by 12.35% in over the last four-week period, additionally sinking by -36.19% over the last 6 months – not to mention a drop of -56.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EPZM stock in for the last two-week period is set at 53.73, with the RSI for the last a single of trading hit 61.83, and the three-weeks RSI is set at 48.19 for Epizyme Inc. [EPZM]. The present Moving Average for the last 50 days of trading for this stock 6.03, while it was recorded at 5.48 for the last single week of trading, and 8.80 for the last 200 days.
Epizyme Inc. [EPZM]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Epizyme Inc. [EPZM] shares currently have an operating margin of -1430.12 and a Gross Margin at +42.56. Epizyme Inc.’s Net Margin is presently recorded at -1469.95.
Return on Total Capital for EPZM is now -54.70, given the latest momentum, and Return on Invested Capital for the company is -56.75. Return on Equity for this stock declined to -89.80, with Return on Assets sitting at -51.00. When it comes to the capital structure of this company, Epizyme Inc. [EPZM] has a Total Debt to Total Equity ratio set at 135.17. Additionally, EPZM Total Debt to Total Capital is recorded at 57.48, with Total Debt to Total Assets ending up at 52.25. Long-Term Debt to Equity for the company is recorded at 164.86, with the Long-Term Debt to Total Capital now at 56.40.
Reflecting on the efficiency of the workforce at the company, Epizyme Inc. [EPZM] managed to generate an average of -$762,151 per employee. Receivables Turnover for the company is 4.51 with a Total Asset Turnover recorded at a value of 0.03.Epizyme Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.60 and a Current Ratio set at 6.70.
Earnings per share (EPS) analysis for Epizyme Inc. [EPZM] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EPZM. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Epizyme Inc. go to 38.00%.
Epizyme Inc. [EPZM]: Insider Ownership positions
There are presently around $547 million, or 97.80% of EPZM stock, in the hands of institutional investors. The top three institutional holders of EPZM stocks are: PRIMECAP MANAGEMENT CO/CA/ with ownership of 15,287,477, which is approximately 0.33% of the company’s market cap and around 1.20% of the total institutional ownership; RP MANAGEMENT, LLC, holding 9,166,667 shares of the stock with an approximate value of $52.52 million in EPZM stocks shares; and REDMILE GROUP, LLC, currently with $48.79 million in EPZM stock with ownership of nearly -3.505% of the company’s market capitalization.
Positions in Epizyme Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 63 institutional holders increased their position in Epizyme Inc. [NASDAQ:EPZM] by around 3,821,720 shares. Additionally, 65 investors decreased positions by around 5,017,133 shares, while 27 investors held positions by with 86,568,906 shares. The mentioned changes placed institutional holdings at 95,407,759 shares, according to the latest SEC report filing. EPZM stock had 17 new institutional investments in for a total of 1,991,535 shares, while 27 institutional investors sold positions of 1,906,095 shares during the same period.